From Financial Modeling Prep: 2025-03-07 07:00:07

Theriva Biologics, Inc. (AMEX:TOVX) focuses on developing therapies for cancer and diseases using biologics. With a ROIC of -92.88% and a WACC of 5.46%, Theriva’s capital efficiency is inefficient compared to Imunon, Inc. (IMNN) with a ROIC of 442.47% and WACC of 3.90%, showcasing strong growth potential. Fresh Tracks Therapeutics, Inc. (FRTX) falls in between with a ROIC of 3.53% and WACC of 9.55%. LogicMark, Inc. (LGMK) and Eledon Pharmaceuticals, Inc. (ELDN) struggle with negative ROICs, indicating challenges in capital utilization.



Read more at Financial Modeling Prep:: Theriva Biologics, Inc. (AMEX:TOVX) Financial Anal…